121 results about "1,3-Butanediol" patented technology

A non-naturally occurring microbial organism having a 1,3-butanediol (1,3-BDO) pathway includes at least one exogenous nucleic acid encoding a 1,3-BDO pathway enzyme or protein expressed in a sufficient amount to produce 1,3-BDO. A method for producing 1,3-BDO that includes culturing the this non-naturally occurring microbial organism under conditions and for a sufficient period of time to produce 1,3-BDO.

The ketogenic diet (KD) has therapeutic implications in many disease states. It was hypothesized ketone precursor supplementation would elevate blood ketone levels to therapeutic ranges (2-7 mM) without need for dietary restriction. The effects of ketogenic agents were tested on blood glucose, ketones, and lipids with a 28-day dose escalation study in male Sprague-Dawley rats: R,S-1,3-Butandiol (BD), acetoacetate ketone ester (KE), and control (H2O) (n≧8). Days 1-28, rats received a daily 5 g / kg intragastric gavage, based on previous toxicology studies. Once weekly, whole blood samples (10 μl) were acquired for analysis of glucose and βHB at 0, 0.5, 1, 4, 8, and 12 hours after test substance administration, or until βHB returned to baseline. At day 1 and 28, 10 μL of whole blood were collected to measure triglycerides, total cholesterol, and HDL concentration. Significant elevation of blood ketone was observed with a significant inverse relationship with blood glucose for the duration of the experiment. There were no significant changes in the lipid panel for any of the substances. There were significant reductions in body weight when animals were treated with either BD or KE as compared to control.

The invention provides a non-naturally occurring microbial organism having n-propanol and isopropanol pathways, 1,4-butanediol (14-BDO) and isopropanol pathways, 1,3-butanediol (13-BDO) and isopropanol pathways or methylacrylic acid (MAA) and isopropanolpathways. The microbial organism contains at least one exogenous nucleic acid encoding an enzyme in each of the respective n-propanol, 14-BDO, 13-BDO or MAA and isopropanol pathways. The invention additionally provides a method for co-producing n-propanol and isopropanol, 14-BDO and isopropanol, 13-BDO and isopropanol or MAA and isopropanol. The method can include culturing an n-propanol and an isopropanol co-producing microbial organism, where the microbial organism expresses at least one exogenous nucleic acid encoding an n-propanol, an isopropanol, a 14-BDO, a 13-BDO and / or a MAA pathway enzyme in a sufficient amount to produce each of the respective products, under conditions and for a sufficient period of time to produce each of the respective products.

The invention relates to a curable sealant composition broadly comprising a resealable, swellable, reactive sealant and free radical initiator; said resealable, swellable reactive sealant comprises monofunctional monomer(s), multifunctional monomer(s), reactive polymer such as unsaturated styrenic block copolymer, swellable additive, and optional components. The monofunctional monomer is a vinyl ester derivative of versatic acid with C9-C12 carbon atoms, or monoacrylate, monomethacrylate, monoacrylamide, or monomethacrylamide. The multifunctional monomer are di-, tri-, tetra-, and / or penta-functional monomers with vinyl, acrylate, methacrylate, acrylamide, or methacrylamide functionality, such as tricyclodecane dimethanol diacrylate, trimethylolpropane trimethacrylate, 1,3-butylene glycol dimethacrylate or a mixture thereof. The reactive unsaturated polymer is a styrenic block copolymer such as SBS, SIS, S-I / B-S, I-SEBS-I, and mixtures of two or more of these. The swellable additive is selected from saturated block copolymers such as SEBS, SEPS, SEEPS, and I-SEBS-I, or a mixture of these. Free radical initiators are preferably peroxides, although others are acceptable.